Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma

Sonia T Anand; Kelli K Ryckman; Rebecca J Baer; Mary E Charlton; Patrick J Breheny; William W Terry; Kord Kober; Scott Oltman; Elizabeth E Rogers; Laura L Jelliffe-Pawlowski; Elizabeth A Chrischilles

doi:10.1080/14767058.2021.1922378

Journal article

Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma

Sonia T Anand, Kelli K Ryckman, Rebecca J Baer, Mary E Charlton, Patrick J Breheny, William W Terry, Kord Kober, Scott Oltman, Elizabeth E Rogers, Laura L Jelliffe-Pawlowski, …

The journal of maternal-fetal & neonatal medicine, Vol.35(25), pp.6751-6758

05/12/2021

DOI: 10.1080/14767058.2021.1922378

PMID: 33980115

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/8586052View

Open Access

Abstract

Leukemia and lymphoma are cancers affecting children, adolescents, and young adults and may affect reproductive outcomes and maternal metabolism. We evaluated for metabolic changes in newborns of mothers with a history of these cancers. A cross-sectional study was conducted on California births from 2007 to 2011 with linked maternal hospital discharge records, birth certificate, and newborn screening metabolites. History of leukemia or lymphoma was determined using ICD-9-CM codes from hospital discharge data and newborn metabolite data from the newborn screening program. A total of 2,068,038 women without cancer history and 906 with history of leukemia or lymphoma were included. After adjusting for differences in maternal age, infant sex, age at metabolite collection, gestational age, and birthweight, among newborns born to women with history of leukemia/lymphoma, several acylcarnitines were significantly (p < .001 - based on Bonferroni correction for multiple testing) higher compared to newborns of mothers without cancer history: C3-DC (mean difference (MD) = 0.006), C5-DC (MD = 0.009), C8:1 (MD = 0.008), C14 (MD = 0.010), and C16:1 (MD = 0.011), whereas citrulline levels were significantly lower (MD = −0.581) among newborns born to mothers with history of leukemia or lymphoma compared to newborns of mothers without a history of cancer. The varied metabolite levels suggest history of leukemia or lymphoma has metabolic impact on newborn offspring, which may have implications for future metabolic consequences such as necrotizing enterocolitis and urea cycle enzyme disorders in children born to mothers with a history of leukemia or lymphoma.

Leukemia

acylcarnitines

amino acid

lymphoma

metabolite

newborn

Details

Title: Subtitle: Metabolic differences among newborns born to mothers with a history of leukemia or lymphoma
Creators: Sonia T Anand - University of Iowa
Kelli K Ryckman - University of Iowa
Rebecca J Baer - University of California San Diego
Mary E Charlton - University of Iowa
Patrick J Breheny - University of Iowa
William W Terry - University of Iowa
Kord Kober - University of California, San Francisco
Scott Oltman - University of California, San Francisco
Elizabeth E Rogers - University of California, San Francisco
Laura L Jelliffe-Pawlowski - University of California, San Francisco
Elizabeth A Chrischilles - University of Iowa
Resource Type: Journal article
Publication Details: The journal of maternal-fetal & neonatal medicine, Vol.35(25), pp.6751-6758
DOI: 10.1080/14767058.2021.1922378
PMID: 33980115
NLM abbreviation: J Matern Fetal Neonatal Med
ISSN: 1476-7058
eISSN: 1476-4954
Publisher: Taylor & Francis
Grant note: DOI: 10.13039/100000054, name: National Cancer Institute, award: P30 CA086862-18S6
Language: English
Electronic publication date: 05/12/2021
Academic Unit: Pharmacy; Stead Family Department of Pediatrics; Epidemiology; Biostatistics
Record Identifier: 9984193398902771

Metrics

13 Record Views

2 Times Cited - Web of Science